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dexmedetomidine in patients undergoing
transurethral resection of the prostate with
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Jeongmin Kim, Won Oak Kim, Hye-Bin Kim and Hae Keum Kil*Abstract
Background: Dexmedetomidine (DMT), a highly selective α2-adrenoceptor agonist, has been used safely as a
sedative in patients under regional anesthesia. The purpose of this study was to determine the 50% effective dose
(ED50) of single-dose DMT to induce adequate light sedation in elderly patients in comparison with younger
patients undergoing transurethral resection of the prostate (TURP) with spinal anesthesia.
Methods: Forty-two male patients were recruited. The young age group (Group Y) included patients 45 to 64 years
old and the old age group (Group O) included patients 65 to 78 years old. After the spinal anesthesia was performed, a
pre-calculated dose of DMT was administered for 10 min. The Observer’s Assessment of Alertness/Sedation (OAA/S)
scale, bispectral index score (BIS) were assessed then at 2-min intervals for 20 min. A modified Dixon’s up-and-down
method was used to determine the ED50 of the drug for light sedation (OAA/S score 3/4). In the recovery room,
regression times of the motor and sensory blocks were recorded.
Results: The ED50 of DMT was 0.25 (95% C.I. 0.15-0.35) μg/kg in Group O and 0.35 (95% C.I. 0.35-0.45) μg/kg in Group Y
(p = 0.002). The ED95 was 33% lower in Group O compare with Group Y (0.38 (95% C.I. 0.29-0.39) μg/kg vs. 0.57 (95% C.I.
0.49-0.59) μg/kg). The regression time of sensory block was longer in Group O than in Group Y (109.0 ± 40.2 min vs.
80.0 ± 31.6 min) (p = 0.014).
Conclusion: The single-dose of DMT for light sedation was lower by 21% in Group O compare with Group Y
underwent TURP with spinal anesthesia.
Trial registration: ClinicalTrials.gov identifier: NCT01665586. Registered July 31, 2012.
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Although spinal block is the most common anesthetic
method for transurethral resection of the prostate
(TURP), patients may still experience adverse effects
during surgery. Satisfactory sedation relieves a patient’s
psychological and physiological stress and increases the
patient’s acceptance of regional anesthesia. However,* Correspondence: hkkil@yuhs.ac
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unless otherwise stated.excessive sedation can cause adverse cardiorespiratory
effects, masking the early signs of TURP syndrome, [1,2]
and even increase the incidence of postoperative delir-
ium in elderly patients [3,4]. Our challenge was to in-
duce appropriately light sedation during TURP with
spinal anesthesia, while maintaining the patient’s arousa-
bility, cooperativity, and cardiopulmonary stability.
Dexmedetomidine (DMT), a potent and highly select-
ive α2-adrenoceptor agonist, has been safely used to sed-
ate patients under regional anesthesia [5-7]. DMT
induces potent sedation through its action on the locusis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Observer’s assessment of alertness/sedation scale
[17]
1 Does not respond to mild prodding or shaking
2 Responds to mild prodding or shaking
3 Responds only after name is spoken loudly or repeatedly
4 Lethargic response to name spoken in normal tone
5 Responds readily to name spoken in normal tone
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in sleep regulation and respiratory control [8]. Com-
pared to traditional sedatives such as midazolam and
propofol, patients treated with DMT have better arousa-
bility and cooperation, minimal respiratory depression,
[9,10] and better postoperative cognitive function. More-
over, intravenous DMT hastens the onset and prolongs
the duration of spinal block [11-13]. Thus, DMT could
be a useful alternative for sedation in patients undergo-
ing TURP with low-dose spinal anesthesia. DMT is usu-
ally given initially as a bolus, followed by continuous
infusion. Single-dose DMT can also provide adequate
sedation during short procedures under spinal anesthesia
[7,11-15]. However, previous literature investigating the
single-dose use of DMT for sedation during spinal
anesthesia in elderly patients is scarce [7,11].
The aim of this study was to determine the 50% effective
dose (ED50) and 95% effective dose (ED95) of single-dose
DMT to induce adequate sedation in elderly patients com-
pared to those in younger patients undergoing TURP with
spinal anesthesia.
Methods
Clinical setting
The present study was performed at Severance Hospital
from July 2012 to December 2013. This study was con-
ducted in accordance with principles of Good Clinical
Practice and was approved by the Institutional Research
Board of Severance Hospital (reference number 4-2011-
0927) and all patients gave written informed consent.
The study was registered at ClinicalTrails.Gov with the
number NCT01665586. The patients were fully in-
formed the sedation assessment during spinal anesthesia.
Exclusion criteria included the infection on puncture
sites, coagulopathy disorders, allergy to local anesthetics,
psychiatric history, and neurological diseases. Forty-two
patients of ASA physical status I or II and who were
scheduled to undergo elective TURP were recruited.
Subjects were divided into two groups by the patient’s
age. Patients in the young age group (Group Y) were
between 45 and 64 years old and those in the old age
group (Group O) were 65 to 78 years old. One
anesthesiologist prepared the study drug (DMT) in a prep-
aration room. All patients and the observational investiga-
tors were blinded to the administered dose of DMT. One
millilitre (100 μg) of DMT (Precedex®, Hospira Inc., Lake
Forest, USA) was diluted with 49 ml of normal saline
(2 μg/ml) in a 50 ml syringe.
Spinal anesthesia
No premedication was given. Standard monitors and bis-
pectral index (BIS) monitors (BIS vista monitor Revision
3.0, Aspect Medical Systems, Norwood, MA, USA) were
applied in the operating room. Prior to spinal block,300 ml of lactated Ringer’s solution was administrated
intravenously. Spinal puncture was performed with a 25
gauge Quincke needle at L3/4 in lateral decubitus pos-
ition. After confirmation of free-flow and clear cerebro-
spinal fluid, 6 mg of hyperbaric bupivacaine (Marcaine®
Spinal Heavy: Astra, Sodertalje, Sweden) was adminis-
tered intrathecally over 10–15 s. The pin-prick test was
performed then every 2 min at the mid-thoracic line bi-
laterally. The peak block level was defined as the same
block level that persisted at four consecutive pin-prick
tests. When the peak sensory block was determined, the
degree of motor block was assessed using a modified
Bromage Scale (in which 0 = no paralysis; 1 = unable to
raise extended leg; 2 = unable to flex knee; 3 = unable to
flex ankle) [16]. After the lithotomy position was done
for surgical preparation, the pre-calculated amount of
DMT solution was infused for 10 min using an infusion
pump (Orchestra® Module DPS, Fresenius Vial S. A. S.
Le Grand Chemin 38590 Brézins, France). A modified
Dixon’s up-and-down method was used to determine
the ED50 of DMT to obtain a light sedation level of an
Observer’s Assessment of Alertness/Sedation scale
(OAA/S) 4/3 [17]. After the infusion was completed, a
second anesthesiologist evaluated the OAA/S scales, BIS
scores, and vital signs every 2-min intervals for 20 min.
The initial DMT dose in the first patient was 0.6 μg/kg.
If the patient had a lethargic response when his name
was called in a normal tone or responds only after name
is spoken loudly or repeatedly (OAA/S scale 4/3) at any
time point of assessment, it was defined as a successful
sedation (Table 1) [18]. If the patient showed the OAA/S
scale ≤2, he was awakened with tactile stimulation. If
targeted sedation (OAA/S <5) was not obtained within
20 minutes, it was defined as failed sedation. Depending
on the responses, the subsequent dose of DMT was de-
creased or increased by 0.1 μg/kg for the next patient in
a stepwise fashion. Recruitment continued until six inde-
pendent pairs (from successful sedation to failed sed-
ation) would give a reliable estimation of the adequate
light sedation dose of DMT in each group. Mean arterial
pressure (MAP), heart rate (HR), and SpO2 were re-
corded every 5 minutes during anesthesia, at the end of
surgery, at arrival and 30 min of the post anesthetic care
unit (PACU).
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30% decrease from the baseline value. Bradycardia was
defined as heart rate < 45 bpm. Hypotension or brady-
cardia was treated with intravenous ephedrine or atro-
pine. When the SpO2 was <92%, supplemental oxygen
was given via face mask.
In the PACU, the times to sensory regression of 2-
dermatomes and to motor recovery to a Bromage scale
of 0 were evaluated. Postoperative pain was assessed
using a verbal numerical rating scale (vNRS: 0 = no pain;
10 = worst possible pain) at 6 and 24 h postoperatively.
Pain ≥ 5 vNRS was treated with 50 mg of intravenous
tramadol. The time to the first analgesic request was
recorded.
Statistical analysis
Statistical analysis was performed using PASW Statistics
19™ (SPSS Inc., Chicago, IL, U.S.A.). Data was analysed by
isotonic regression using the pooled-adjacent-violators al-
gorithm (PAVA) to interpolate ED50 (83% C.I.) and ED95
(95% C.I.). Independent t-tests, chi-square tests, Fisher’s
exact tests, or Mann–Whitney tests were used to compare
complication rates, and postoperative pain scores between
the two groups. A linear mixed model was used to analyse
the hemodynamic variables across the two groups. In each
group, MAP and HR changes were compared to baseline
values using t-tests. The correlation of the BIS and the
OAA/S scale was analyzed with a mixed model in each
group. Values are expressed as mean ± standard deviation
(SD), mean (95% C.I.), or as numbers. Each investigation
of two groups was carried out by Dixon’s up-and-down
method. The sample size was based on Dixon’s method,
which requires at least six pairs of failure-success to calcu-
late half maximal effective concentration (EC50) [19]. Pa-
tients were recruited until six pairs of consecutive up and
down (success and failure) adjustment of the DMT dose
was achieved. Statistical significance was defined by a
P value < 0.05.Figure 1 Dixon’s up-and-down method; success (closed circle), failureResults
The sequences of successful and failed sedation are pre-
sented in Figure 1. The estimated ED50 of DMT was sig-
nificantly different between the old and young groups
[0.25 (95% C.I. 0.15-0.35) μg /kg vs. 0.35 (95% C.I. 0.35-
0.45) μg/kg, p < 0.05]. When the values were interpolated
using isotonic regression with PAVA and the bootstrap
method, the ED50 (83% C.I.) and ED95 (95% C.I.) of DMT
were still significantly different between Group O and
Group Y (Table 2).
In both groups, MAP gradually decreased after the
DMT infusion, but heart rate decreased continuously
during the experiment compared to the baseline values
(p < 0.05) (Figure 2). By linear mixed model analysis, the
MAP of Group O decreased significantly more than that
of Group Y (p < 0.05), but heart rate was not signifi-
cantly different between the two groups (p > 0.05).
Forty-two patients were enrolled (Group Y = 22,
Group O = 20) (Figure 3). Mean age of Group Y was
58 years old, whereas that of Group O was 72 years old.
Patients’ height, weight and BSA were similar between
the groups (each p > 0.05). The duration of surgery, max-
imum sensory block level and baseline hemodynamics
were not significantly different between the groups (each
p > 0.05). Comorbidities (including hypertension, dia-
betes mellitus, coronary artery disease and other dis-
eases) were present in 85% of patients in Group O and
41% of patients in Group Y. The sensory block regres-
sion time was longer in Group O than in Group Y
(109.0 ± 40.2 min vs. 80.0 ± 31.6 min, p < 0.05), but
motor recovery time was similar in both groups. Postop-
erative 6 hours pain score was low in Group O compare
with the Group Y (2.1 ± 0.8 vs. 3.2 ± 2.0, p < 0.05). But
no difference showed in postoperative 24 hrs (Group O
vs. Group Y, 1.4 ± 0.8 vs. 1.9 ± 1.5, p > 0.05). Transient
hypotension occurred after DMT infusion in 27.3% of
Group O (6/22) and 35% in Group Y (7/20). These
hypotensive events were self-limited and ephedrine was(open circle).
Figure 2 Intraoperative hemodynamic changes.
Table 2 Dixon’s method and isotonic regression
Drug dose (μg/kg) Group Y (n = 22) Group O (n = 20)
Dixon’s method
ED50 (95% C.I.) 0.35 (0.35-0.45) 0.25 (0.15-0.35)
Isotonic regression method
ED50 (83% C.I.)† 0.41 (0.38-0.45) 0.24 (0.19-0.3)
ED95 (95% C.I.)‡ 0.57 (0.49-0.59) 0.38 (0.29-0.39)
ED50; 50% effective dose, ED95; 95% effective dose, C.I.; confidence interval
Dixon’s method p value (non-parametric): 0.009.
†Isotonic regression method 83% Confidence interval: do not overlap.
‡Isotonic regression method 95% Confidence interval: do not overlap.
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decreased below 92% during DMT infusion but was im-
proved with O2 administration. No one showed OAA/S
≤2 during the procedure. BIS and OAA/S were moderately
associated in the Group O and strongly associated in the
Group Y during sedation. (r = 0.489, p < 0.05 vs. r = 0.604,
p < 0.05).
Discussions
The first question in this study sought to determine the
50% effective dose (ED50) and 95% effective dose (ED95)
of single-dose DMT to induce adequate sedation in eld-
erly patients undergoing TURP with spinal anesthesia.
The current study found that the ED95 of a single-dose
DMT to induce light sedation was 0.38 μg/kg (95% C.I.
Figure 3 Consort diagram.
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0.57 μg/kg (95% C.I. 0.49-0.59) in patients between 45
and 64 years old. The most important clinically relevant
finding was the ED95 of single-dose DMT in elderly pa-
tients was 67% that of younger patients.
Manufacturer suggests that sedation with DMT can be
achieved with 0.2-0.7 μg/kg/hr after 1.0 μg/kg loading
dosage [20]. However, in elderly patients, excessive sed-
ation can easily occur when recommend dosage of DMT
was used. Park et al. found that excessive sedation with
a Ramsay score of 5/6 occurred in 46% of patients
treated with 0.5 μg/kg DMT and 60% of patients treated
with 1 μg/kg DMT in elderly patients [11]. In compari-
son, none of the 30- to 40-year-old patients showed ex-
cessive sedation of OAA/S ≤ 2 after a 0.5 μg /kg DMT
infusion [15]. Therefore, minimal optimum dose of
DMT to avoid over sedation should be determined in
elderly patients. The findings of this study suggest that
we should reduce the dose of DMT for elderly patients
as one third of recommend dose for young patients.
These results match those observed in earlier studies
that suggest that the required dosage of DMT in elderly
patients is half that of the recommended young adult
dose [21,22].
Although, these findings cannot be extrapolated to all pa-
tients, the present study provides additional evidence with
respect to pharmacokinetics of DMT in elderly patient
undergoing spinal anesthesia. Generally, elderly patients are
more sensitive to sedative agents. Less medication is usually
required to achieve a desired clinical effect, and drug effectis often more pronounced and prolonged than we expected.
However, to date there has been little agreement on the
dosage of DMT in elderly patient undergoing neuraxial
blockade or peripheral blockade. Whilst this study did not
confirm the pharmacokinetics of DMT, it would be helpful
to set out a practical guideline of DMT for the elderly pa-
tient undergoing neuraxial blockade or peripheral blockade.
If a planned regional blockade is done successfully, a rela-
tively small single-bolus dose of DMT <0.5 μg/kg would be
needed to reduce discomfort, anxiety and restless in elderly
patients undergoing surgical procedure within 30 minutes.
There are several possible explanations for this result.
First of all, spinal anesthesia may increase sensitivity to a
sedative agent, explaining the low ED95 for an OAA/S
sedation scale [23]. Since Tverskoy et al. reported that
spinal block with bupivacaine decreased the hypnotic re-
quirement of midazolam, thiopental, and propofol,
[24,25] several studies have confirmed these findings
[23,26,27]. Especially in the early stage of spinal block,
spinal anesthesia decreases afferent input and this re-
duces the sedative hypnotic requirement. Another pos-
sible explanation for this is that spinal analgesic spread
is greater and analgesic recovery is prolonged in elderly
patients as compared to younger patients [28-31]. These
characteristics may be related to the different pharmaco-
kinetic and pharmacodynamic properties of local anes-
thetics with advancing age.
Most studies in the field of DMT have only focussed
on the sedative dose as a general intravenous anesthetic,
few studies have investigated single-dose DMT use in
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reported that single-dose DMT (0.25 μg/kg, 0.5 μg/kg,
or 1 μg/kg) improved spinal anesthesia by increasing
block duration, increasing postoperative analgesia and
achieving patient satisfaction [7,11,15]. Intravenous
DMT is known to prolong the anesthetic duration and
improve the analgesic characteristics associated with
spinal block [7,11-14]. Although the underlying mechan-
ism for this is still unclear, supraspinal, direct analgesic,
and vasoconstricting effects are thought to be involved
[9,12]. We found that sensory block duration was longer
in the old age group than the young age group (109.0 ±
40.2 min vs. 80.0 ± 31.6 min) despite similar peak sen-
sory block levels. These results are consistent with those
of other studies.
One unanticipated finding was that BIS and OAA/S
were moderately associated in the Group O and strongly
associated in the Group Y during sedation. Although,
there were significant correlations between OAA/S and
BIS (Group O, r = 0.489, p < 0.05 vs. Group Y, r = 0.604,
p < 0.05), we thought this statistical correlation between
BIS values and OAA/S scores may not be meaningful in
this dose-response study. Several studies have demon-
strated that BIS is not a sensitive tool for measuring sed-
ation induced with spinal anesthesia [18]. Furthermore,
it has age-dependent differences, [32,33]. Accordingly,
we used BIS as an adjunctive for clinical reference to the
OAA/S scale. EEG-based monitors did not reliably dis-
tinguish between light and deep sedation [34]. Because,
our targeted sedation depth was OAA/S 3/4, relatively
light sedation, BIS value could not be appropriate in this
setting. In addition, Kasuya et al. reported a discrepancy
between OAA/S and BIS scoring when DMT was used
as the sedative agent [35] and elderly patients may lose
consciousness at a higher BIS score than do young
adults [33]. Therefore, these results need to be inter-
preted with caution.Conclusions
In conclusion, our results suggest that a single-dose of
DMT for elderly patients undergoing spinal anesthesia
for TURP should be reduced to two-thirds of the dose
for younger patient. However, careful hemodynamic moni-
toring is imperative in elderly patients administered DMT
for sedation under regional anesthesia, because small
doses of DMT (<0.3 μg/kg) can result in bradycardia and
hypotension.Abbreviations
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